Drug Trial Radar · NCT06477237
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
408
Actual
Start
Mar 29, 2024
Primary completion
Nov 15, 2024
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Huabo Biopharm Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in the treatment of moderate to severe plaque psoriasis in adults.
Conditions
- Psoriasis
Interventions
HB0017 Q4WBiological
HB0017 at W0,1,2,4,8+HB0017Q4W
HB0017 Q8WBiological
HB0017 at W0,1,2,4,8+HB0017Q8W
placeboBiological
placebo at W0,1,2,4,8+HB0017Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving PASI 75 response at Week 12Time frame: Week 12
- Proportion of subjects achieving sPGA 0/1 response at Week 12Time frame: Week 12
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Beijing Friendship Hospital
Beijing, China
China-Japan Friendship hospital
Beijing, China
Peking University People's Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Jilin University Second Hospital
Changchun, China
The first hospital of Jilin University
Changchun, China
Xiangya Hospital of Central South University
Changsha, China
Affiliated Hospital of Chengde Medical University
Chengde, China
Sichuan Provincial People's Hospital
Chengdu, China
West China Hospital of Sichuan University
Chengdu, China
Chongqing Traditional Chinese Medicine Hospital
Chongqing, China
Dongguan People's Hospital
Dongguan, China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China
Dermatology Hospital of Southern Medical University
Guangzhou, China
Guangdong Provincial People's Hospital
Guangzhou, China
Hangzhou First People's Hospital
Hangzhou, China
Hangzhou Third People's Hospital
Hangzhou, China
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
The Second Affiliated Hospital of Harbin Medical University
Harbin, China
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Jiaxing First Hospital
Jiaxing, China
Shandong Dermatology Hospital
Jinan, China
Jining First People's Hospital
Jining, China
The First Affiliated Hospital of Kunming Medical University
Kunming, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, China
The Second Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
Dermatology Hospital of Jiangxi Province
Nanchang, China
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Jiangsu University Affiliated Hospital
Nanjing, China
Ningbo Second Hospital
Ningbo, China
Shanghai Dermatology Hospital
Shanghai, China
People's Hospital of Liaoning Province
Shenyang, China
Shenzhen People's Hospital
Shenzhen, China
Shiyan People's Hospital
Shiyan, China
The Second Hospital of Shanxi Medical University
Taiyuan, China
Wenzhou Medical University Affiliated First Hospital
Wenzhou, China
Wuhan University People's Hospital
Wuhan, China
The First Affiliated Hospital of Wannan Medical College
Wuhu, China
Wuxi Second People's Hospital
Wuxi, China
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.